1. |
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021, 71(3): 209-249.
|
2. |
Sperber AD, Bangdiwala SI, Drossman DA, et al. Worldwide prevalence and burden of functional gastrointestinal disorders, results of rome foundation global study. Gastroenterology, 2021, 160(1): 99-114. e113.
|
3. |
中华人民共和国国家卫生健康委员会. 原发性肝癌诊疗指南 (2022年版). 肿瘤防治研究, 2022, 49(3): 251-276.
|
4. |
Liu D, Song T. Changes in and challenges regarding the surgical treatment of hepatocellular carcinoma in China. Biosci Trends, 2021, 15(3): 142-147.
|
5. |
Xu XF, Xing H, Han J, et al. Risk factors, patterns, and outcomes of late recurrence after liver resection for hepatocellular carcinoma: a multicenter study from China. JAMA Surg, 2019, 154(3): 209-217.
|
6. |
Wang JJ, Li H, Li JX, et al. Preoperative gamma-glutamyltransferase to lymphocyte ratio predicts long-term outcomes in intrahepatic cholangiocarcinoma patients following hepatic resection. World J Gastroenterol, 2020, 26(13): 1501-1512.
|
7. |
Ke Q, Xiang F, Xiao C, et al. Exploring the clinical value of preoperative serum gamma-glutamyl transferase levels in the management of patients with hepatocellular carcinoma receiving postoperative adjuvant transarterial chemoembolization. BMC Cancer, 2021, 21(1): 1117. doi: 10.1186/s12885-021-08843-z.
|
8. |
Chraa D, Naim A, Olive D, et al. T lymphocyte subsets in cancer immunity: friends or foes. J Leukoc Biol, 2019, 105(2): 243-255.
|
9. |
Pang RW, Poon RT. Diagnosis: novel prognostic biomarkers in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol, 2012, 9(12): 691-692.
|
10. |
Khemlina G, Ikeda S, Kurzrock R. The biology of hepatocellular carcinoma: implications for genomic and immune therapies. Mol Cancer, 2017, 16(1): 149. doi: 10.1186/s12943-017-0712-x.
|
11. |
Samstein RM, Lee CH, Shoushtari AN, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet, 2019, 51(2): 202-206.
|
12. |
Zhang LX, Lv Y, Xu AM, et al. The prognostic significance of serum gamma-glutamyltransferase levels and AST/ALT in primary hepatic carcinoma. BMC Cancer, 2019, 19(1): 841. doi: 10.1186/s12885-019-6011-8.
|
13. |
Zhang H, Zhou Y, Li Y, et al. Predictive value of gamma-glutamyl transpeptidase to lymphocyte count ratio in hepatocellular carcinoma patients with microvascular invasion. BMC Cancer, 2020, 20(1): 132. doi: 10.1186/s12885-020-6628-7.
|
14. |
Gehring AJ, Ho ZZ, Tan AT, et al. Profile of tumor antigen-specific CD8 T cells in patients with hepatitis B virus-related hepatocellular carcinoma. Gastroenterology, 2009, 137(2): 682-690.
|
15. |
Corti A, Franzini M, Paolicchi A, et al. Gamma-glutamyltransferase of cancer cells at the crossroads of tumor progression, drug resistance and drug targeting. Anticancer Res, 2010, 30(4): 1169-1181.
|
16. |
隋璐璐, 刘小方, 许政. 联合检测外周血hTERTmRNA及GGTmRNA-H表达对小肝癌早期诊断的价值. 中国普外基础与临床杂志, 2011, 18(1): 59-62.
|
17. |
Ostroumov D, Fekete-Drimusz N, Saborowski M, et al. CD4 and CD8 T lymphocyte interplay in controlling tumor growth. Cell Mol Life Sci, 2018, 75(4): 689-713.
|
18. |
申兵兵, 朱文杰, 江建新. 免疫细胞浸润与肝癌预后的相关性研究进展. 中国普外基础与临床杂志, 2022, 29(7): 953-957.
|